Sexual dimorphic studies of various parameters of the femur play an important role in forensic studies. Various femur morphometric parameters help estimate an individual’s age, sex, and stature from unknown skeletal remains. This research was done to analyze maximum length, trochanteric oblique length, and diameter of the femur head for sexual dimorphism. The study was done on 200 (128 male & 72 female) Indian adult human femora, which were fully ossified, dry, and free from deformity. The maximum length of the femur (L), trochanteric oblique length (TOL), and vertical diameter of the head (VDH) were measured using an osteometric board and digital Vernier calipers. The mean length of the femur was 436.88 mm in males and 402.38 mm in females, respectively. The mean trochanteric oblique length of the femur was 423.78 mm in males and 387.18 mm in females, respectively. The mean vertical diameter of the femur head was 43 mm in males and 38.19 mm in females, respectively. Depending upon the results of this study, it was concluded that the mean values of maximum length, trochanteric oblique length, and vertical diameter of the femur head are significantly higher in males than females. These parameters are useful and reliable for sexual dimorphism in anthropometric and forensic studies, especially in identifying skeletal remains. These differences can also be considered in selecting or designing the exact ranges of the gender-specific prosthesis for Orthopedic surgeries.

Background: The treatment of locally advanced head and neck carcinoma has been a combination of chemotherapy and radiation. The higher incidences of recurrence and metastasis warrant the search for an alternative therapy for better patient outcomes. This study was designed to evaluate the effect of gefitinib in conjunction with concurrent chemoradiation in locally advanced stages III and IV head and neck cancer.Methodology: The patients were equally divided into two groups: Group I received cisplatin 100 mg/m2 on the first, 22nd, and 43rd days together with the radiation, whereas Group II was given the same treatment as Group I together with oral doses of gefitinib 250 mg on a daily basis, starting two weeks prior to radiotherapy and continuing until the completion of it. The dose of radiotherapy was 2 Gray (Gy) per fraction given over a period of five days per week to a maximum of 70 Gy in locally higher grades of head and neck neoplasms. The evaluation was performed in accordance with the RECIST (Response Evaluation Criteria in Solid Tumors) criteria, which include stable disease (SD), progressing disease (PD), partial response (PR), and complete response (CR). Salvage chemotherapy, potential surgical intervention, or palliative care was presented to patients with remaining or recurring diseases. The grading of the patients for acute and chronic radiation morbidity was done according to the Radiation Therapy Oncology Group (RTOG) criteria for toxicity during radiation treatment and at each subsequent follow-up. Parameters such as site, nodal involvement, stage, tumor status, and Eastern Cooperative Oncology Group (ECOG) were recorded.Results: On comparing the patient characteristics, no statistical significance was observed. The overall response was seen in 24 (80%) and 28 (83.33%) patients in Group I and Group II, respectively (p = 0.08). All patients in Group I and Group II reported xerostomia as an acute/chronic adverse event of chemotherapy. Similarly, mucositis, dysphagia, and diarrhea were observed in all the patients, and no statistical difference was observed. Seventeen (56.67%) patients in Group II had complaints of skin rashes, while four (13.33%) patients in Group I had similar complaints (p = 0.01). Conclusion:The study concludes that encouraging results were observed in comparing overall response after the addition of oral gefitinib to the traditional treatment of locally advanced head and neck neoplasms.